NCT04743479 Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)
| NCT ID | NCT04743479 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Changhai Hospital |
| Condition | Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2020-12-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2020-12-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pancreatic cancer is one of the most fatal malignancies with a 5-year survival rate of only \~6%\[1\]. The reasons for this high mortality rate can be attributed to several factors, of which perhaps the most important is delayed diagnosis due to vague symptoms and consequently missed opportunities for surgical resection. Therefore, the ability to detect pancreatic cancer at an early, more curable stage is urgently needed. Identifying risk factors and biomarkers of early pancreatic cancer could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. Thus, the investigators propose this longitudinal study entitled, "Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)" in order to generate clinical data sets and bank serial blood specimens of high risk individuals.
Eligibility Criteria
Inclusion Criteria: * Subject is able and willing to provide informed consent and sign an informed consent form. * Subject or authorized representative must be willing to complete a detailed questionnaire. * Subject must meet one of the following criteria: 1. New onset diabetes (diagnosed within the past 3 years) 2. Familial pancreatic cancer 3. Inherited syndromes associated with pancreatic cancer (including Hereditary pancreatitis, Familial atypical multiple mole and melanoma syndrome, Hereditary nonpolyposis colon cancer, Peutz-Jeghers syndrome, Hereditary breast and ovarian cancer syndromes, etc) 4. Pancreatic cystic neoplasm (including IPMN, MCN) 5. Chronic pancreatitis Exclusion Criteria: * Subject has been diagnosed with pancreatic cancer or other malignant tumors in the last 5 years; * Subject has any medical condition that contraindicates high-resolution MRI or CT; * Subject cannot be followed up or is participating in other clinical trials.
Contact & Investigator
Gang Jin, M.D.
STUDY CHAIR
Department of general surgery, Changhai Hospital
Frequently Asked Questions
Who can join the NCT04743479 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 75 Years, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04743479 currently recruiting?
Yes, NCT04743479 is actively recruiting participants. Contact the research team at lilly_wang@126.com for enrollment information.
Where is the NCT04743479 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT04743479 clinical trial?
NCT04743479 is sponsored by Changhai Hospital. The principal investigator is Gang Jin, M.D. at Department of general surgery, Changhai Hospital. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.